IDEAYA Biosciences, Inc. (FRA:30J)
Germany · Delayed Price · Currency is EUR | Market Cap | 3.11B +57.4% |
| Revenue (ttm) | 204.93M +3,244.7% |
| Net Income | -153.20M |
| EPS | -1.71 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 60 |
| Open | 31.98 |
| Previous Close | 31.82 |
| Day's Range | 31.98 - 31.98 |
| 52-Week Range | 22.60 - 36.06 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 4, 2026 |
About IDEAYA Biosciences
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhib... [Read more]
Financial Performance
In 2025, IDEAYA Biosciences's revenue was $218.71 million, an increase of 3024.43% compared to the previous year's $7.00 million. Losses were -$113.70 million, -58.58% less than in 2024.
Financial numbers in USD Financial StatementsNews
Ideaya Biosciences appoints Michael White as president, R&D
IDEAYA Biosciences (IDYA) announced the promotion of Dr. Michael White, from Chief Scientific Officer to President, Research and Development. White has served as CSO since 2021.
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap...
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap...
IDEAYA Biosciences Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
A diversified precision oncology pipeline is advancing, with darovasertib nearing NDA submission and multiple phase III studies ongoing. DLL3 ADC and MTAP/KRAS programs target high unmet needs, supported by strategic collaborations and a data-driven approach to capital allocation. Key updates are expected at the upcoming R&D Day.
IDEAYA Biosciences Transcript: Citigroup’s Biopharma Back to School Summit 2026
Late-stage oncology assets are advancing, with NDA submission for darovasertib nearly complete and commercial launch expected next year. IDE849 is moving to phase III, and new data on multiple pipeline assets and AI-driven innovations will be presented at ESMO and an R&D Day in London.
IDEAYA Biosciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Final NDA submission for darovasertib is imminent, with positive FDA feedback and new data to be presented at ESMO. The pipeline advances include a phase III DLL3 ADC trial in small cell lung cancer, strategic collaborations with Roche, and expansion into PRMT5 and CDKN2A programs.
Ideaya Biosciences price target raised to $57 from $54 at Guggenheim
Guggenheim raised the firm’s price target on Ideaya Biosciences (IDYA) to $57 from $54 and keeps a Buy rating on the shares while previewing upcoming data for IDE849 due in…
Ideaya Biosciences doses first patient in OptimUM-11 trial
Ideaya Biosciences (IDYA) announced that the first patient has been dosed in OptimUM-11, a global Phase 3 registrational trial evaluating darovasertib, an oral protein kinase C inhibitor, in combinati...
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma
Global Phase 3 trial will evaluate the darovasertib and crizotinib combination in primary uveal melanoma patients with increased risk of metastasis following completion of local therapy OptimUM-11 exp...
IDEAYA Biosciences Transcript: Wells Fargo 21st Annual Healthcare Conference
Darovasertib is nearing NDA completion with a potential launch in the first half of next year, while significant updates are expected for the HLA-A*02 positive population and the DLL3 franchise. The pipeline is advancing with PRMT5 and RAS collaborations, and key catalysts include new trial initiations and data readouts.
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therape...
Ideaya Biosciences announces Type C meeting with FDA for IDE849 trial design
Ideaya Biosciences (IDYA) announced a successful FDA Type C meeting to determine the Phase 3 registrational trial design for IDE849, a potential delta-like ligand 3, or DLL3-targeting Topo-I-payload a...
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
Based on FDA Type C meeting, targeting to initiate a randomized Phase 3 registrational trial for IDE849 monotherapy by year-end 2026 in ES-SCLC, with ORR by BICR as the primary endpoint for potential ...
Ideaya Biosciences enters IDE892 collaboration with Genentech
Ideaya Biosciences (IDYA) announced it has entered into a clinical collaboration with Genentech, a member of Roche (RHHBY), to evaluate the efficacy and safety of IDE892, its investigational MTA-coope...
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
IDEAYA entered into a clinical collaboration to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6620, Genentech's Phase 1 KRAS G12D inh...
Ideaya Biosciences price target lowered to $42 from $45 at Citizens
Citizens lowered the firm’s price target on Ideaya Biosciences (IDYA) to $42 from $45 and keeps an Outperform rating on the shares following the company’s Q2 earnings report, citing “new…
Ideaya Biosciences price target raised to $60 from $58 at Wedbush
Wedbush raised the firm’s price target on Ideaya Biosciences (IDYA) to $60 from $58 and keeps an Outperform rating on the shares after the company reported second quarter financials and…
Ideaya Biosciences price target lowered to $59 from $63 at Truist
Truist lowered the firm’s price target on Ideaya Biosciences (IDYA) to $59 from $63 and keeps a Buy rating on the shares. Ideaya delivered continued execution in Q2, with darovasertib’s…
Ideaya Biosciences reports Q2 EPS ($1.22), consensus ($1.05)
Reports Q2 revenue $8.86M, consensus $7.45M. “This quarter marked another successful step forward in our mission to deliver new, potentially best-in-class precision therapies for people with cancer. W...
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway under the real-time oncology ...
IDEAYA Biosciences Earnings release: Q2 2026
IDEAYA Biosciences released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
IDEAYA Biosciences Quarterly report: Q2 2026
IDEAYA Biosciences has published its Q2 2026 quarterly earnings report on August 4, 2026.
IDEAYA Biosciences Slides: Corporate presentation
IDEAYA Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on August 3, 2026.
Ideaya Biosciences initiates monotherapy expansion in IDE892 trial
Ideaya Biosciences (IDYA) announced that initiation of Part 2 monotherapy expansion has been achieved in its Phase 1/2 clinical trial evaluating IDE892, a methylthioadenosine-cooperative inhibitor of ...
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers
IDE892 is a potential best-in-class PRMT5 inhibitor with 1,400-fold selective MTA-PRMT5 cooperative binding vs SAM-PRMT5 cooperative binding, and CYP3A4 IC50 greater than 45 micromolar with no time-de...